Board summary
Key figures
33,759
Registered population
63.7% aged 18–64
15.4%
Aged 65+
ICB 19.0% · England 17.9%
19.2%
Ethnic minority (non-White)
7.0% Asian · England 9.6%
95.6%
In IMD quintile 1
ICB 31.9% · England 21.0%
~27,827
Core20 residents (est.)
Resident basis; registered basis ~32,121 · see page 3
4,779
Hypertension register
+0.64% in 3 yrs · England +5.60%
600
SMI register
7.1% of Liverpool (LAD)'s
1,470
COPD register
Reviews +13.06% in 3 yrs
Forecast to 2030
5,031
Hypertension patients, 2030
+252 on today
64.9%
QRISK ≥20% on statins, 2030
+0.04pp over 3 yrs
3.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Non-frail diabetes glycaemic control trails benchmarks.
Only 48.4% (850 of 1,756 patients) achieve HbA1c at or below 58 mmol/mol versus 53.6% in Liverpool, 56.2% in the ICB and 57.4% nationally.
Pre-school booster uptake lags the target.
Age-5 4-in-1 booster coverage is 61.6% in Q1 2025/26, below the 95.0% target by 33.4 pp (ICB 82.9%, England 80.9%).
Diabetes primary-prevention statin prescribing exceeds England.
Statin treatment in diabetes without CVD reaches 75.4% (Liverpool 71.6%, ICB 72.4%, England 73.2%), rising +5.3% over 2023 to 2025 (England +2.1%).
Population, age and ethnicity
A younger demographic with 20.9% aged 0-17 and 15.4% aged 65+ may shape demand
Across 33,759 registered patients, 20.9% (7,060 patients) are aged 0-17 (Liverpool 19.8%, ICB 19.2%, England 19.6%) and 15.4% (5,192 patients) are aged 65+ (Liverpool 15.6%, ICB 19.0%, England 17.9%). By Census usual residents, 80.8% are White (Liverpool 84.0%, ICB 93.0%, England 81.1%), giving a 19.2% ethnic minority share, with Asian (7.0%) and Black (5.0%) residents exceeding ICB levels. At Islington House Medical Centre, White residents comprise 74.8% and Asian residents 11.7%. Projected population growth to 2030 is 2.5% (Liverpool 3.0%, ICB 2.3%, England 2.3%), though projection methodology is unverified.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 48.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is pervasive across the network with 95.6% of patients in Core20 areas
Across the PCN, 95.6% of registered patients live in Core20 areas, above Liverpool (54.9%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 1.5 (England 5.5). Priory Medical Centre has the largest volume at an estimated 9,887 Core20 patients. Concentration reaches 100.0% at Mere Lane Group Practice, while Islington House Medical Centre records 83.9%. Great Homer Street Medical Centre also records 100.0%, spanning a practice range of 16.1 pp. Resident Core20 estimates (27,827) and registered lists use different bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
600
SMI register
1.73% recorded prevalence
188
Learning disability register
0.54% recorded prevalence
11
Care homes, 471 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
Recorded severe mental illness prevalence is 1.7% (600 patients), above Liverpool (1.4%), the ICB (1.1%) and England (1.0%), while learning disability prevalence is 0.5% (188 patients; comparators 0.6%). Catchment facilities include 11 care homes with 471 beds, though capacity does not establish registered residents. Severe mental illness prevalence is above Liverpool, the ICB and England, so physical-health checks for this cohort may be the larger workload to protect.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.7% (England 1.0%). Annual SMI blood pressure checks (76.6%) and BMI checks (74.9%) trail England (83.4% and 82.1%). Physical health monitoring requires prioritisation across the severe mental illness cohort.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,779
Hypertension register
+0.64%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+5.92pp
BP control, under 80
≤140/90 · −1.31pp aged 80+
+252
More patients by 2030
Forecast 5,031 (13.94%)
Hypertension case-finding and control
Hypertension prevalence is 13.8% (4,779 patients), below England (15.2%), Liverpool (14.0%) and the ICB (16.8%), while three-year register growth of +0.6% trails England (+5.6%). Blood pressure control under 80 is 63.6%, lagging England (67.8%), Liverpool (67.0%) and the ICB (66.4%), despite recent readings reaching 87.6%. For patients aged 80 and over, control is 79.5% (England 81.2%), falling 1.6% over three years (England +2.2%). Register differences are unadjusted for age and do not confirm under-detection. Lower blood pressure control under age 80 than England indicates an opportunity to prioritise systematic medication titration and recall across the PCN.
Lipids and statins
Statin uptake reaches 64.8% for QRISK ≥ 20% patients (England 63.6%) and 75.4% in diabetes without CVD (England 73.2%), though QRISK therapy growth stalled at +0.1% over three years (England +6.2%). Stalled growth despite higher uptake than England indicates a need to prioritise reviewing eligible high-risk patients not currently prescribed therapy.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 65,370 | £1.50 | £1.71 | £1.86 | £98,055 |
| Cardiovascular (all), 2025 | 92,737 | £4.33 | £4.37 | £3.33 | £401,551 |
In 2026, 65,370 items were prescribed for lipid-regulating drugs at £1.50 per item, below England (£1.86), Liverpool (£1.82) and the ICB (£1.71). Across these items, the PCN spent £23,533 less than at England's unit cost. Lower unit spend than England allows the PCN to prioritise therapy optimisation and review rather than cost reduction.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+11.85%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.44%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence is 4.2% (1,470 patients), exceeding Liverpool (3.0%), the ICB (2.5%) and England (1.9%), though prevalence fell 6.3% over three years (England +2.6%). While COPD reviews reached 77.2% (England 76.4%), asthma reviews trail at 62.2% (England 65.7%, Liverpool 64.3%), leaving about 860 patients unreviewed. Paediatric asthma prescribing reaches 3,934 items per 1,000 aged 5-19 (England 1,488 rate). Proactive asthma recall and inhaler management require prioritisation alongside sustained COPD reviews to manage high community respiratory need.
Cancer register and children's immunisation
Recorded cancer prevalence is 3.1% (1,077 patients; England 3.8%, ICB 4.3%). In childhood immunisation (Q1 2025/26), age-5 MMR dose 2 coverage is 66.3% (ICB 84.4%, England 82.8%) against the 95.0% target. The 4-in-1 booster coverage is 61.6% (ICB 82.9%, England 80.9%). Pre-school booster shortfalls leave children unprotected before school entry, requiring systematic call-and-recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers (7,482 of 13,490 with a known stage; 72.8% staged overall) were diagnosed at stage 1 or 2, against 55.3% in England, sitting 19.5 pp below the 75.0% national ambition and requiring about 2,640 extra early-stage diagnoses. ICB early-stage share rose 2.6 pp from 2013 to 2022. This system data does not represent PCN performance. Locally, cervical screening in women aged 25-49 is 56.1% (England 66.8%), falling 2.4% over three years (England -1.0%), while breast screening is 64.0% (England 69.9%). Screening uptake below national benchmarks could delay early cancer identification.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional Jul 2026 data, Liverpool Women's NHS Foundation Trust achieved 75.7% on the 28-day faster diagnosis standard (standard 75.0%), above Liverpool University Hospitals NHS Foundation Trust (75.5%) but below the ICB (77.2%) and England (79.3%). On the 62-day standard, Liverpool Women's reached 69.1% (standard 85.0%), lagging Liverpool University Hospitals (73.3%), the ICB (76.2%) and England (71.2%). Across all diagnostic tests, 6.5% waited 6+ weeks at Liverpool Women's, compared to 11.5% at Liverpool University Hospitals and 23.1% in England. Acute waiting times reflect system provider pressures rather than primary care delivery.
| Pathways within standard (%) | Liverpool Women's | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.73 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 85.42 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 69.09 | 73.26 | 77.96 | 76.23 | 71.16 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). Provisional data for Jun 2026 recorded 162,760 community care activities for Liverpool residents and 1,332,205 across NHS Cheshire and Merseyside Integrated Care Board. Older adults aged 65+ accounted for 65.4% of Liverpool contacts (83,300 of 127,380), though these figures reflect wider resident activity rather than PCN delivery. Coordinating with community services may help support the network's older residents.
Practice variation and patient experience
Ease of phone contact varies across practices by 42.7 pp, from 29.9% to 72.6%
In 2025/26, England overall QOF achievement was 92.5%. Mere Lane Group Practice achieved 80.8%, while Islington House Medical Centre achieved 90.4%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Islington House | 101 | 83.9 | 70.3% | 85.8% | 87.3% |
| Priory | 121 | 95.3 | 32.9% | 72.1% | 74.4% |
| Great Homer | 85 | 100.0 | 64.8% | 59.3% | 73.6% |
| Townsend | 115 | 96.5 | 72.6% | 68.8% | 71.0% |
| Mere Lane | 74 | 100.0 | 29.9% | 69.7% | 59.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 measures trail England over three years, led by clinical process drops
Across 25 compared measures, 13 trail England's three-year change. Trailing areas are led by smoking cessation support offered, down 5.4 pp to 87.7% (England +0.1 pp to 94.2%), and psychosis alcohol recording, down 1.6 pp to 76.2% (England +5.4 pp to 81.8%). Heart failure reviews rose +1.0% to 64.2% (England +8.7% to 78.5%), and QRISK ≥ 20% statin therapy grew +0.1% (England +6.2%). Conversely, strengths include three-year gains in breast screening (+30.6% vs +8.4% in England), COPD reviews (+13.1% vs +2.8%), and asthma reviews (+11.8% vs +4.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Heart failure reviews
Alcohol record (psychosis)
QRISK statin treatment
Cancer register
Breast screening (53-70)
COPD reviews
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (471 beds) | n/a | Schools (catchment) | 77 | n/a |
| Children's centres | 3 | 26 | Places of worship | 31 | 240 |
| Libraries | 1 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 9 | 91 | Primary academies | 3 | 20 |
| Special schools | n/a | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Asthma annual reviews: 62.2% reviewed in 12 months (Liverpool 64.3%, England 65.7%; denominator includes PCAs), leaving an estimated 859 (about 860) of 2,271 register patients unreviewed. For discussion: practices could run a single-template asthma recall combining annual reviews with inhaler prescribing checks and flexible after-school or holiday slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined physical health checks for SMI
SMI register (600 patients; 1.7% vs England 1.0%): 12-month BP checks at 76.6% (Liverpool 79.8%, ICB 81.3%, England 83.4%) and BMI checks at 74.9% (England 82.1%); patient count not sized. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Hypertension titration and BP control recall
Hypertension register (4,779 patients; 13.8% vs England 15.2%): BP <= 140/90 mmHg under age 80 is 63.6% (ICB 66.4%, Liverpool 67.0%, England 67.8%, incl. PCAs); patient gap not sized. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Language and communication access review (p2) | White | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined physical health checks for SMI (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Hypertension titration and BP control recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
